Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cordlife India is the Indian stem cell banking and diagnostics subsidiary of Singapore-listed Cordlife Group, focused on private umbilical cord blood, cord lining/tissue, and related newborn biological sample banking. The company operates processing, testing, cryopreservation, and storage services for families, and also offers selected clinical diagnostic services such as newborn metabolic screening and prenatal diagnostics. Its India laboratory in West Bengal is described by the company as AABB accredited and also holds CAP, NABL, WHO GMP, and DCGI-related credentials cited by the parent group. Cordlife India is a commercial-stage healthcare services business rather than a therapeutics developer, with revenues tied to stem cell preservation contracts and associated diagnostics. For a biotech analyst, the key point is that this is a healthcare services and biobanking operator with cryostorage infrastructure, not a drug-discovery biotech with a conventional clinical pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cordlife India.